Restoring eIF2B activity using PKR-like ER kinase (PERK) inhibitors or genetic approaches has been shown to protect against neurodegeneration in preclinical models of prion disease, frontotemporal dementia, and ALS [63]. Here, EIF2AK3 is linked to prion disease.